Ruth Karron, MD
Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health (JHSPH)
2
1
0
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (2)
Research Network
Collaboration Network
Research Areas & Affiliations
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
D. Nigel Thomas, Ph.D.
Novavax, Inc.
Shared therapeutic areas:
Paul Wisman
Pediatric Research of Charlottesville
Shared therapeutic areas:
lanjuan li
Shulan (Hangzhou) Hospital
Shared therapeutic areas:
Michael Bell
Accel-West Volusia Pediatrics
Shared therapeutic areas:
Craig Curtis, MD
Compass Research
Shared therapeutic areas:
Jeffrey Stewart
Family Medical Associates
Shared therapeutic areas:
Ruth A. Karron, MD
Johns Hopkins Bloomberg School of Public Health
Shared therapeutic areas:
Worked with same sponsors:
William Simon
New Medical Healthcare
Shared therapeutic areas:
Ernesto Ramirez, PhD
Evidation Health
Shared therapeutic areas:
Gates MRI
Gates Medical Research Institute
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (2)
Showing 2 of 2 trials
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
All 2 trials loaded